PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in⦠read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
$18.01
Price+2.92%
$0.51
$457.644m
Small
8.6x
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$7.644m
-
1y CAGR-
3y CAGR-
5y CAGR-$11.864m
-
1y CAGR-
3y CAGR-
5y CAGR$0.80
-
1y CAGR-
3y CAGR-
5y CAGR$407.933m
$602.635m
Assets$194.702m
Liabilities$22.361m
Debt3.7%
-0.7x
Debt to EBITDA-$239.698m
-
1y CAGR-
3y CAGR-
5y CAGR